한글목차

세계의 마이크로니들 인플루엔자 백신 시장은 2024년에 11억 8,000만 달러로 평가되었으며, 2030년까지 CAGR 5.96%로 성장하여 16억 7,000만 달러에 달할 것으로 예측됩니다.

세계 마이크로니들 인플루엔자 백신은 보통 패치에 내장된 미세한 바늘을 이용해 인플루엔자 백신을 피부 표층에 투여하는 혁신적인 투여 시스템입니다. 이를 통해 기존 근육 주사에 비해 덜 침습적인 대안을 제공합니다. 이 시장의 성장은 주로 바늘에 대한 두려움을 줄이고 전 세계적으로 환자의 순응도를 높이기 위한 무통 자가접종 백신 접종 방법에 대한 수요 증가에 의해 주도되고 있습니다.

주요 시장 촉진요인

세계 마이크로니들 인플루엔자 백신 시장은 주로 무통 자가 접종 방식에 대한 수요 증가와 마이크로니들 기술의 지속적인 발전에 영향을 받고 있습니다. 최소침습적 백신 접종에 대한 요구는 광범위한 주사바늘 공포증에 대한 대응과 환자의 순응도 향상으로 이어져, 백신 접종에 대한 장벽으로 작용해 온 문제를 해결하는 중요한 촉진제가 되고 있습니다.

주요 시장 과제

새로운 약물전달 시스템에 대한 복잡하고 엄격한 규제 승인 절차는 전 세계 마이크로니들 인플루엔자 백신 시장 확대에 큰 장벽으로 작용하고 있습니다. 의료기기와 생물학적 제제를 결합한 제품인 마이크로니들백신은 임상시험에서 광범위하고 엄격한 요건을 충족해야 합니다.

주요 시장 동향

용해성 마이크로니들 기술로의 전환은 백신 투여의 획기적인 발전이며, 날카로운 생물학적 위험 폐기물을 제거하여 환자의 편안함과 안전성을 향상시킵니다. 이 생분해성 고분자 기반 패치는 피부 내에서 용해되어 정확하고 지속적인 항원 방출을 가능하게 합니다. 이를 통해 백신의 효능을 향상시키고, 투여량을 줄일 수 있습니다.

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 마이크로니들 인플루엔자 백신 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 제품 유형별(중실 마이크로니들, 중공 마이크로니들)
  • 백신 유형별(3가 인플루엔자 백신, 4가 인플루엔자 백신)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 마이크로니들 인플루엔자 백신 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 마이크로니들 인플루엔자 백신 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 마이크로니들 인플루엔자 백신 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 중동 및 아프리카의 마이크로니들 인플루엔자 백신 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트
  • 남아프리카공화국

제10장 남미의 마이크로니들 인플루엔자 백신 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 콜롬비아
  • 아르헨티나

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병
• 제품 출시
• 최근 동향

제13장 세계의 마이크로니들 인플루엔자 백신 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제15장 경쟁 구도

• Debiotech S.A.
• NanoPass Technologies Limited
• Becton, Dickinson and Company
• FluGen, Inc.
• CosMED Pharmaceuticals Co., Ltd.
• Microdermics Inc.
• TSRL Inc.
• Vaxess Technologies Inc.
• Pfizer, Inc.
• Merck & Co., Inc.

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

영문목차

The Global Microneedle Flu Vaccine Market, valued at USD 1.18 Billion in 2024, is projected to experience a CAGR of 5.96% to reach USD 1.67 Billion by 2030. The global microneedle flu vaccine is an innovative delivery system utilizing microscopic needles, typically integrated into a patch, to administer the influenza vaccine into the superficial layers of the skin, offering a less invasive alternative to traditional intramuscular injections. This market's growth is primarily driven by the increasing demand for painless and self-administered vaccination methods, aiming to reduce needle phobia and enhance patient compliance globally.

Key Market Drivers

The global microneedle flu vaccine market is primarily influenced by the rising demand for painless and self-administered vaccination methods and continuous advancements in microneedle technology. The desire for less invasive vaccine delivery is a significant driver, addressing widespread needle phobia and improving patient compliance, which traditionally pose barriers to vaccination uptake. For instance, according to a study published in the *Journal of Multidisciplinary Healthcare*, in May 2024, "Prevalence, factors associated and management of needle phobia among the general population in Saudi Arabia and Egypt", approximately 36.5% of adult participants reported experiencing needle phobia, highlighting a substantial population that could benefit from alternative administration routes.

Key Market Challenges

The complex and stringent regulatory approval process for novel drug delivery systems presents a significant obstacle to the expansion of the global microneedle flu vaccine market. As products combining both a medical device and a biologic, microneedle vaccines are subject to extensive and rigorous requirements for clinical trials. These trials must rigorously demonstrate the safety, efficacy, and consistent manufacturing scalability of the integrated system.

Key Market Trends

The shift towards dissolvable microneedle technologies marks a notable advancement in vaccine delivery, offering enhanced patient comfort and safety by eliminating sharp biohazardous waste. These biodegradable polymer-based patches dissolve within the skin, facilitating precise and sustained antigen release, which can improve vaccine efficacy and potentially allow for reduced dosage requirements. This trend underscores the industry's commitment to innovation in materials science for medical applications.

Key Market Players

• Debiotech S.A.
• NanoPass Technologies Limited
• Becton, Dickinson and Company
• FluGen, Inc.
• CosMED Pharmaceuticals Co., Ltd.
• Microdermics Inc.
• TSRL Inc.
• Vaxess Technologies Inc.
• Pfizer, Inc.
• Merck & Co., Inc.

Report Scope:

In this report, the Global Microneedle Flu Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Microneedle Flu Vaccine Market, By Product Type:

• Solid Microneedle
• Hollow Microneedle

Microneedle Flu Vaccine Market, By Vaccine Type:

• Trivalent Flu Vaccine
• Quadrivalent Flu Vaccine

Microneedle Flu Vaccine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Microneedle Flu Vaccine Market.

Available Customizations:

Global Microneedle Flu Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Microneedle Flu Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Solid Microneedle, Hollow Microneedle)
  • 5.2.2. By Vaccine Type (Trivalent Flu Vaccine, Quadrivalent Flu Vaccine)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Microneedle Flu Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Vaccine Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Microneedle Flu Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Vaccine Type
  • 6.3.2. Canada Microneedle Flu Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Vaccine Type
  • 6.3.3. Mexico Microneedle Flu Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Vaccine Type

7. Europe Microneedle Flu Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Vaccine Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Microneedle Flu Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Vaccine Type
  • 7.3.2. France Microneedle Flu Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Vaccine Type
  • 7.3.3. United Kingdom Microneedle Flu Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Vaccine Type
  • 7.3.4. Italy Microneedle Flu Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Vaccine Type
  • 7.3.5. Spain Microneedle Flu Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Vaccine Type

8. Asia Pacific Microneedle Flu Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Vaccine Type
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Microneedle Flu Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Vaccine Type
  • 8.3.2. India Microneedle Flu Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Vaccine Type
  • 8.3.3. Japan Microneedle Flu Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Vaccine Type
  • 8.3.4. South Korea Microneedle Flu Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Vaccine Type
  • 8.3.5. Australia Microneedle Flu Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Vaccine Type

9. Middle East & Africa Microneedle Flu Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Vaccine Type
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Microneedle Flu Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Vaccine Type
  • 9.3.2. UAE Microneedle Flu Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Vaccine Type
  • 9.3.3. South Africa Microneedle Flu Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Vaccine Type

10. South America Microneedle Flu Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Vaccine Type
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Microneedle Flu Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Vaccine Type
  • 10.3.2. Colombia Microneedle Flu Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Vaccine Type
  • 10.3.3. Argentina Microneedle Flu Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Vaccine Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Microneedle Flu Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Debiotech S.A.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. NanoPass Technologies Limited
• 15.3. Becton, Dickinson and Company
• 15.4. FluGen, Inc.
• 15.5. CosMED Pharmaceuticals Co., Ltd.
• 15.6. Microdermics Inc.
• 15.7. TSRL Inc.
• 15.8. Vaxess Technologies Inc.
• 15.9. Pfizer, Inc.
• 15.10. Merck & Co., Inc.

16. Strategic Recommendations

17. About Us & Disclaimer